Taiwan's biotechnology industry is making a significant impact at the 2024 BIO International Convention in San Diego. Organized by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) under the Ministry of Economic Affairs, the Taiwan delegation includes representatives from various government bodies, research institutions, and over 60 delegates.
Taiwan Delegation Fostering Global Collaborations and Innovations
The delegation aims to showcase Taiwan's biotech innovations and expand global business operations through internationalpartnerships.At the Taiwan Pavilion, cutting-edge technologies and products will be highlighted, fostering cross-border technological and commercialcollaborations.
The Taiwanese delegation at BIO 2024 highlights the country’s dynamic biotechnology sector and its contributions to global healthcareadvancements.With innovative solutions ranging from cancer therapies to AI-driven medicaldevices,Taiwan's biotech companies are forging international partnerships and expanding their marketreach.
The BIO International Convention serves as a pivotal platform for these companies to showcase their cutting-edge technologies and foster globalcollaborations.This fruitful event yieldedover 1,250matchmaking meetings, and some on-site business collaborations, including order placement, MOU signings, and NDAsignings.
Based on the information provided, GeneOnline wrapped up eight prominent companies showcasing their innovativesolutions (other companies please see our US-BIO-FOCUS special articles).
Tanvex BioPharma: Leading the CDMO Service Landscape
Tanvex BioPharma debuts at BIO 2024 with its "Tanvex CDMO" brand, offering a comprehensive one-stop CDMOsolution.Partnering with local firms like Alcami and Argonaut, Tanvex provides services from upstream to downstream, including ADC CDMOcapabilities.Chairman Chen Linzheng emphasizes Tanvex’s expertise in cancer treatment and antibody drug development, bolstered by their FDA-compliantGMP facilityin the U.S. Tanvex's participation underscores its commitment to expanding itsCDMO service chainand enhancing drug developmenttimelines.
KriSan Biotech: Expanding ADC Capabilities
KriSan Biotech presents its end-to-endADC platform, aiming to partner with global biologicscompanies.With a focus onlinker-payload selection,scale-up, andGMP production, KriSan addresses the growing ADCmarket.Chairman Dr. Rongjin Lin highlights KriSan’s expertise in small molecule design and strategic alliances, including the expansion of their facility in Tainan Science Park to support ADCprojects.KriSan’s participation marks a significant step in becoming a leading CDMO forsmall moleculesandADCs.
Everfront Biotech: Pioneering Cancer Treatment
Everfront Biotech showcases its latest drug development achievements, particularly the innovative treatment forglioblastoma,Cerebraca®Wafer.This FDA-designated orphan drug offers localized,sustained drug delivery post-surgery, overcoming the blood-brainbarrier.Clinical trials indicate a median survival period significantly higher than existingtreatments.Everfront’s focus on unmet medical needs andorphan drugdevelopment positions it as a key player in pioneering cancertherapies.
Simpson Biotech: Innovative Yeast Expression Platform
Simpson Biotech introduces its proprietaryyeast expression systemforrecombinant proteinproduction.This platform utilizes patentedStarch Binding Proteinfor cost-effective, scalable proteinpurification.Simpson Biotech’s versatile expression system supports various applications, includingfood enzymesandmedical proteins, and has already seen commercial success with global enzymecompanies.Their participation at BIO 2024 highlights their commitment to transforming research outcomes into viable marketsolutions.
Caliway Biopharmaceuticals: Advancing Clinical Trials
Caliway Biopharmaceuticals presents its lead pipeline candidate,CBL-514, showing promising results inreducing subcutaneous fatand treatingDercum’s diseaseandcellulite.With Phase 2 studies demonstrating significant efficacy, Caliway aims to leverage the BIO International Convention to attract international partnerships and further clinicaladvancements.Their focus on medicalaestheticsandinflammatorydiseases showcases their innovative approach to biopharmaceuticaldevelopment.
AB DigiHealth: AI-Driven Fertility Solutions
AB DigiHealth unveils its AI software medical device,icONE, designed toenhance fertilitytreatments.The system predicts the best embryos for implantation with a 92% accuracy rate, accelerating infertility treatmentprocesses.Having receivedFDA Class I software medical device registration, icONE is set to make a significant impact in the U.S.market.AB DigiHealth’s collaboration with global partners and their focus onprecision maternal-fetal medicinehighlight their technologicalprowess.
PrecisemAb Biotech: Universal Antibody Lock Technology
PrecisemAb Biotech showcases itsUniversal Antibody Lock technology,enhancing the safety and efficacy of antibodydrugs.This platform is applicable to various antibody drug formats, includingADCsandbispecificantibodies.Chairman Yu Yunqi emphasizes the technology’s potential inreducing drug side effectsandincreasing therapeuticeffectiveness.PrecisemAb’s participation aims to expand their international collaborations and marketpresence.
MoleculeX: Innovative Oral Care Solutions
MoleculeX Co., Ltd. presents its bioadhesive patch forcancer-induced oral mucositiscare.This innovative product has received Taiwan FDA approval and is poised for international marketexpansion.MoleculeX’s technology offers effective mucosal wound care, improving the quality of life for cancerpatients.Their participation at BIO 2024 underscores their commitment to advancing supportive cancer caresolutions.
